Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 128

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 128
---
 in...      The U. S. patents will expire in 2027, 2028, 2034, 2037 and 2041 respectively. The UK patent will expire in 2034. The European patent will expire in 2035. Any other patents derived from the pen...  
  Test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Because of the extensive time
required for clinical development and regulatory review of a drug we may develop, it is possible that, before any of our drug candidates
can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing
any advantage of any such patent. If appropriate, the Company may seek to extend the period during which it has exclusive rights to a
product by pursuing patent term extensions and marketing exclusivity periods that are available from the regulatory authorities of certain
countries (including the United States) and the EPO.

Even though the Company has
certain patent rights, the ability to obtain and maintain protection of biotechnology and pharmaceutical products and processes such as
those we intend to develop and commercialize involves complex legal and factual questions. No consistent policy regarding the breadth
of claims allowed in such patents has emerged to date in the U. S. The scope of patent protection outside the United States is even more
uncertain. Changes in the patent laws or in interpretations of patent laws in the United States and other countries have diminished (and
may further diminish) our ability to protect our inventions and enforce our IP rights and, more generally, could affect the value of IP.

While we have already secured
rights to a number of issued patents directed to our drug candidates, we cannot predict the breadth of claims that may issue from the
pending patent applications and provisional patents that we have licensed or that we have filed. Substantial scientific and commercial
research has been conducted for many years in the areas in which we have focused our development efforts, which has resulted in other
parties having a number of issued patents, provisional patents and pending patent applications relating to such areas. The patent examiner
in any particular jurisdiction may take the view that prior issued patents and